

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |           |  |
|---|--|-----------|--|
| (51) International Patent Classification 6 :<br><b>A61K 38/08</b>   |  | <b>A1</b> | (11) International Publication Number: <b>WO 96/14858</b><br>(43) International Publication Date: <b>23 May 1996 (23.05.96)</b>  |
| (21) International Application Number: <b>PCT/US95/14764</b><br>(22) International Filing Date: <b>14 November 1995 (14.11.95)</b><br><br>(30) Priority Data:<br>08/337,781      14 November 1994 (14.11.94)      US<br>08/465,775      6 June 1995 (06.06.95)      US<br><br>(71) Applicant: <b>UNIVERSITY OF SOUTHERN CALIFORNIA</b><br>[US/US]; University Park Campus, Los Angeles, CA 90089 (US).<br><br>(72) Inventors: <b>RODGERS, Kathleen</b> ; University of Southern California, University Park Campus, Los Angeles, CA 90089 (US). <b>DIZEREGA, Gere, Stodder</b> ; University of Southern California, University Park Campus, Los Angeles, CA 90089 (US).<br><br>(74) Agent: <b>ALTMAN, Daniel, E.</b> ; Knobbe, Martens, Olson & Bear, Suite 1600, 620 Newport Center Drive, Newport Beach, CA 92660 (US). |  |           | (81) Designated States: <b>AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).</b><br><br><b>Published</b><br><i>With international search report.<br/>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: <b>USE OF ANGIOTENSIN II FRAGMENTS AND ANALOGS THEREOF IN TISSUE REPAIR</b>   |  |           |  |
| (57) Abstract<br><p>Angiotensin II fragments and analogs thereof are useful in accelerating wound healing. These compounds form the basis of compositions useful for accelerating wound healing, in which the active agent is present in an amount effective to accelerate wound healing. Preferably, the compositions are in the form of matrical or micellar solutions.</p>   |  |           |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                        | MR | Mauritania               |
| AU | Australia                | GE | Georgia                               | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                               | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                               | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                 | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                 | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                 | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LJ | Liechtenstein                         | SK | Slovakia                 |
| CM | Cameroon                 | LK | Sri Lanka                             | SN | Senegal                  |
| CN | China                    | LU | Luxembourg                            | TD | Chad                     |
| CS | Czechoslovakia           | LV | Latvia                                | TG | Togo                     |
| CZ | Czech Republic           | MC | Monaco                                | TJ | Tajikistan               |
| DE | Germany                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| DK | Denmark                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | US | United States of America |
| FI | Finland                  | MN | Mongolia                              | UZ | Uzbekistan               |
| FR | France                   |    |                                       | VN | Viet Nam                 |
| GA | Gabon                    |    |                                       |    |                          |

USE OF ANGIOTENSIN II FRAGMENTS AND ANALOGS THEREOF IN  
TISSUE REPAIR

Background of the Invention

This application is a continuation-in-part of Serial No. 08/337,781 filed November 11, 1994, which in turn is a continuation-in-part of Serial No. 08/126,368 filed September 24, 1993, now abandoned.

This invention relates generally to the fields of biochemistry and medicine. More particularly, the present invention relates to compositions and methods for use in accelerating the growth or healing of tissue.

Wounds (i.e., lacerations or openings) in mammalian tissue result in tissue disruption and coagulation of the microvasculature at the wound face. Repair of such tissue represents an orderly, controlled cellular response to injury. All soft tissue wounds, regardless of size, heal in a similar manner. Tissue growth and repair are biologic systems wherein cellular proliferation and angiogenesis occur in the presence of an oxygen gradient. The sequential morphological and structural changes which occur during tissue repair have been characterized in great detail and have in some instances been quantified [Hunt, T.K. et al., "Coagulation and macrophage stimulation of angiogenesis and wound healing," in *The surgical wound*, pp. 1-18, ed. F. Dineen & G. Hildrick-Smith (Lea & Febiger, Philadelphia: 1981)].

The cellular morphology consists of three distinct zones. The central avascular wound space is oxygen deficient, acidotic and hypercarbic, and has high lactate levels. Adjacent to the wound space is a gradient zone of local anemia (ischemia) which is populated by dividing fibroblasts. Behind the leading zone is an area of active collagen synthesis characterized by mature fibroblasts and numerous newly-formed capillaries (i.e., neovascularization). While this new blood vessel growth (angiogenesis) is necessary for the healing of wound tissue, angiogenic agents are in general unable to fulfill the long-felt need of providing the additional biosynthetic effects of tissue repair. Despite the need for more rapid healing of wounds (i.e., severe burns, surgical incisions, lacerations and other trauma), to date there has been only limited success in accelerating wound healing with pharmacological agents.

U.S. Patent 5,015,629 to DiZerega (the entire disclosure of which is hereby incorporated by reference) describes a method for increasing the rate of healing of

wound tissue, comprising the application to such tissue of angiotensin II (AII) in an amount which is sufficient for said increase. The application of angiotensin II to wound tissue significantly increases the rate of wound healing, leading to a more rapid re-epithelialization and tissue repair. The term angiotensin II refers to an octapeptide present in humans and other species having the sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:1]. Angiotensin II is a known pressor agent and is commercially available.

Despite the utility of angiotensin II in accelerating wound healing, there remains a need for additional agents which are useful in promoting wound healing. Moreover, it would be highly advantageous to employ an agent which is less potent than angiotensin II at inducing hypertension.

It is an object of the present invention to provide compositions and methods which do not suffer from the drawbacks of the heretofore-known compositions.

#### Summary of the Invention

The present invention relates to the use of active fragments of AII and analogs thereof in wound healing. These compounds form the basis of compositions useful for accelerating wound healing, the compositions comprising at least one such compound in an amount effective to accelerate wound healing. Preferably, the compositions are in the form of matrical or micellar solutions.

#### Brief Description of the Drawings

The invention may be better understood with reference to the accompanying drawings, in which:

Fig. 1 illustrates the percent increase in wound closure relative to a vehicle-treated control using AIII;

Fig. 2 illustrates the percent of control response in wound closure relative to a vehicle-treated control using various AIII analogs;

Fig. 3 illustrates the percent of control response in wound closure relative to a vehicle-treated control using various AIII analogs;

Fig. 4 illustrates the percent of control response in formation of granulation tissue using various AIII analogs;

Fig. 5 illustrates the percent of control response in formation of granulation tissue using various AIII analogs;

Fig. 6 illustrates the percent of control response in wound closure relative to a vehicle-treated control using various fragments of AII;

Fig. 7 illustrates the percent of control response in wound closure relative to a vehicle-treated control using various fragments of AII;

Fig. 8 illustrates the percent of control response in formation of granulation tissue using various fragments of AII;

Fig. 9 illustrates the percent of control response in formation of granulation tissue using various fragments of AII;

Fig. 10 illustrates the percent of control response in formation of granulation tissue using various fragments of AII;

Fig. 11 illustrates the percent of control response in formation of granulation tissue using various fragments of AII;

Fig. 12 illustrates the percent of control response in formation of granulation tissue using various AIII analogs;


Fig. 13 illustrates the percent of control response in formation of granulation tissue using various AIII analogs; and

Fig. 14 illustrates the percent of control response in wound closure relative to a vehicle-treated control using various fragments of AII.


#### Detailed Description of the Invention

Pursuant to the present invention, wound healing in mammalian tissue is promoted through the use of a composition comprising an effective amount of at least one active fragment of AII or analog thereof. The active agent is generally administered in a matrical or micellar solution and is effective in accelerating re-epithelialization and tissue repair even in very low concentrations.

The active fragments of AII and analogs thereof of particular interest in accordance with the present invention are characterized as comprising a sequence consisting of at least three, and preferably at least four, contiguous amino acids corresponding to a subsequence of groups R<sup>1</sup>-R<sup>8</sup> in the sequence of general formula I



in which R<sup>1</sup> and R<sup>2</sup> together form a group of formula



wherein X is H or a one to three peptide group and a peptide

bond between R<sup>A</sup> and R<sup>B</sup> is labile to aminopeptidase A cleavage;

R<sup>3</sup> is selected from the group consisting of Val, Ala, Leu, Ile, Gly, Pro, Aib, Acpc and Tyr;

R<sup>4</sup> is selected from the group consisting of Tyr, Thr, Ser and azaTyr;

R<sup>5</sup> is selected from the group consisting of Ile, Ala, Leu, Val and Gly;

R<sup>6</sup> is His or Arg;


R<sup>7</sup> is Pro or Ala; and

R<sup>8</sup> is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including R<sup>4</sup> as a terminal Tyr group.

In one class of preferred embodiments, R<sup>A</sup> is suitably selected from Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc. R<sup>B</sup> is suitably selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys. Particularly preferred combinations for R<sup>A</sup> and R<sup>B</sup> are Asp-Arg, Asp-Lys, Glu-Arg and Glu-Lys.

Particularly preferred embodiments of this class include the following: AIII or AII(2-8), Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:2]; AII(3-8), also known as des1-AIII or AIV, Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:3]; AII(1-7), Asp-Arg-Val-Tyr-Ile-His-Pro [SEQ ID NO:4]; AII(2-7), Arg-Val-Tyr-Ile-His-Pro [SEQ ID NO:5]; AII(3-7), Val-Tyr-Ile-His-Pro [SEQ ID NO:6]; AII(5-8), Ile-His-Pro-Phe [SEQ ID NO:7]; AII(1-6), Asp-Arg-Val-Tyr-Ile-His [SEQ ID NO:8]; AII(1-5), Asp-Arg-Val-Tyr-Ile [SEQ ID NO:9]; AII(1-4), Asp-Arg-Val-Tyr [SEQ ID NO:10]; and AII(1-3), Asp-Arg-Val [SEQ ID NO:11]. AII(6-8), His-Pro-Phe [SEQ ID NO:12] and AII(4-8), Tyr-Ile-His-Pro-Phe [SEQ ID NO:13] were also tested and found not to be effective.

Another class of compounds of particular interest in accordance with the present invention are those of the general formula II



in which R<sup>2</sup> is selected from the group consisting of H, Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

R<sup>3</sup> is selected from the group consisting of Val, Ala, Leu, Ile, Gly, Pro, Aib, Acpc and Tyr;

R<sup>4</sup> is selected from the group consisting of Tyr, Thr, Ser and

azaTyr;

R<sup>5</sup> is selected from the group consisting of Ile, Ala, Leu, Val and

Gly;


R<sup>6</sup> is His or Arg;

R<sup>7</sup> is Pro or Ala; and

R<sup>8</sup> is selected from the group consisting of Ile, Phe, Phe(Br) and

Tyr.

A particularly preferred subclass of the compounds of general formula II has  
the formula



wherein R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are as previously defined. Particularly preferred is angiotensin  
III of the formula Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:2]. The fragment AII(4-  
8) was ineffective in repeated tests; this is believed to be due to the exposed tyrosine  
on the N terminus.

In the above formulas, the standard three-letter abbreviations for amino acid  
residues are employed. In the absence of an indication to the contrary, the L-form of  
the amino acid is intended. Other residues are abbreviated as follows:

|                     |  |
|---------------------|--|
| Me <sup>2</sup> Gly | N,N-dimethylglycyl   |
| Bet                 | 1-carboxy-N,N,N-trimethylmethanaminium hydroxide inner salt<br>(betaine) |
| Suc                 | Succinyl   |
| Phe(Br)             | p-bromo-L-phenylalanyl   |
| azaTyr              | aza- $\alpha$ '-homo-L-tyrosyl   |
| Acpc                | 1-aminocyclopentane carboxylic acid                                      |
| Aib                 | 2-aminoisobutyric acid   |
| Sar                 | N-methylglycyl (sarcosine)   |

It has been suggested that AIII and its analogs adopt either a *gamma* or a *beta*  
turn [Regoli, D. et al. (1974) Pharmacology of Angiotensin. Pharmacological  
Reviews 26:69]. In general, it is believed that neutral side chains in positions R<sup>3</sup>, R<sup>5</sup>



and R' may be involved in maintaining the appropriate distance between the active groups in positions R<sup>4</sup>, R<sup>6</sup> and R<sup>8</sup> primarily responsible for binding to receptors and/or intrinsic activity. Hydrophobic side chains in positions R<sup>3</sup>, R<sup>5</sup> and R<sup>8</sup> may also play an important role on the whole conformation of the peptide and/or contribute to formation of a hypothetical hydrophobic pocket.

Appropriate side chains on the amino acid in position R<sup>2</sup> may contribute to affinity of the compounds for target receptors and/or play an important role in the conformation of the peptide. For this reason, Arg and Lys are particularly preferred as R<sup>2</sup>.

For purposes of the present invention, it is believed that R<sup>3</sup> may be involved in the formation of linear or non-linear hydrogen bonds with R<sup>5</sup> (in the *gamma* turn model) or R<sup>6</sup> (in the *beta* turn model). R<sup>3</sup> would also participate in the first turn in a *beta* antiparallel structure (which has also been proposed as a possible structure). In contrast to other positions in general formula I, it appears that *beta* and *gamma* branching are equally effective in this position. Moreover, a single hydrogen bond may be sufficient to maintain a relatively stable conformation. Accordingly, R<sup>3</sup> may suitably be selected from Val, Ala, Leu, Ile, Gly, Pro, Aib, Acpc and Tyr.

With respect to R<sup>4</sup>, conformational analyses have suggested that the side chain in this position (as well as in R<sup>3</sup> and R<sup>5</sup>) contribute to a hydrophobic cluster believed to be essential for occupation and stimulation of receptors. Thus, R<sup>4</sup> is preferably selected from Tyr, Thr, Ser and azaTyr. In this position, Tyr is particularly preferred as it may form a hydrogen bond with the receptor site capable of accepting a hydrogen from the phenolic hydroxyl [Regoli et al. (1974), *supra*].

In position R<sup>5</sup>, an amino acid with a  $\beta$  aliphatic or alicyclic chain is particularly desirable. Therefore, while Gly is suitable in position R<sup>5</sup>, it is preferred that the amino acid in this position be selected from Ile, Ala, Leu and Val.

In the analogs of particular interest in accordance with the present invention, R<sup>6</sup> is His or Arg. The unique properties of the imidazole ring of histidine (e.g., ionization at physiological pH, ability to act as proton donor or acceptor, aromatic character) are believed to contribute to its particular utility as R<sup>6</sup>. For example, conformational models suggest that His may participate in hydrogen bond formation (in the *beta* model) or in the second turn of the antiparallel structure by influencing

the orientation of R'. Similarly, it is presently considered that R' should be Pro in order to provide the most desirable orientation of R<sup>8</sup>. In position R<sup>8</sup>, both a hydrophobic ring and an anionic carboxyl terminal appear to be particularly useful in binding of the analogs of interest to receptors; therefore, Tyr and especially Phe are preferred for purposes of the present invention.

Angiotensin II is one of the most potent vasoconstrictors known, causing constriction of the small arteries that branch to form the capillaries, i.e., the arterioles. The biological formation of angiotensin is initiated by the action of renin on the plasma substrate angiotensinogen. The substance so formed is a decapeptide called angiotensin I which is converted to angiotensin II by the converting enzyme angiotensinase that removes the C-terminal His-Leu residues from angiotensin I.

Studies have shown that the vasoactive product of the renin-angiotensin system, angiotensin II (AII), increases the release of growth factors, mitogenesis, chemotaxis and the release of extracellular matrices of cultured cells that are involved in wound repair [Dzau V.E. et al. (1989) Molecular mechanism of angiotensin in the regulation of vascular and cardiac growth. *J Mol Cell Cardiol* 21 (Supple III):S7; Berk, BC et al. (1989) Angiotensin II stimulated protein synthesis in cultured vascular smooth muscle cells. *Hypertension* 13:305-14; Kawahara, Y, et al. (1988) Angiotensin II induces expression of the c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. *BBRC* 150:52-9; Naftilan, AJ et al. (1989) Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. *J Clin Invest* 83:1419-24; Taubman, MB et al. (1989) Angiotensin II induces c-fos mRNA in aortic smooth muscle. Role of Ca<sup>2+</sup> mobilization and protein kinase C activation. *J Biol Chem* 264:526-530; Nakahara, K et al. (1992) Identification of three types of PDGF-A chain gene transcripts in rabbit vascular smooth muscle and their regulated expression during development and by angiotensin II. *BBRC* 184:811-8; Stouffer GA and GK Owens. (1992) Angiotensin II induced mitogenesis of spontaneously hypertensive rat derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor- $\beta$ . *Circ Res* 70:820; Wolf, G et al. (1992) Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. *Am J Pathol* 140:95-107; Bell, L and JA Madri

(1990) Influence of the angiotensin system on endothelial and smooth muscle cell migration. *Am J Pathol* 137:7-12]. In addition, AII was shown to be angiogenic in rabbit corneal eye and chick chorioallantoic membrane models (Fernandez, LA et al. (1985) Neovascularization produced by angiotensin II. *J Lab Clin Med* 105:141; LeNoble, FAC et al. (1991) Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. *Eur J Pharmacol* 195:305-6]. Therefore, AII may accelerate wound repair through increased neovascularization, growth factor release, reepithelialization and production of extracellular matrix. Through an increase in the flow of blood and nutrients to an injured tissue, AII may increase the rate of wound repair. AII may also accelerate wound repair through the generation of growth factors at the site of injury. Exogenous addition of growth factors has been shown to accelerate wound repair through a variety of mechanisms [Grotendorst, GR et al. (1985) Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats. *J Clin Invest* 76:2323-9; Mustoe, TA et al. (1987) Accelerated healing of incisional wounds in rats induced by transforming growth factor- $\beta$ . *Science* 237:1333-5; Pierce, GF et al. (1988) In vivo incisional wound healing augmented by platelet-derived growth factor and recombinant c-sis gene homodimeric proteins. *J Exp Med* 167:974-87; Lynch, SE et al. (1989) Growth factors in wound healing. *J Clin Invest* 84:640-6; Greenhalgh, DG et al. (1990) PDGF and FGF stimulate wound healing in the genetically diabetic mouse. *Am J Pathol* 136:1235-46]. Recent studies showed that AII increased neointima formation in the carotid artery and aorta after injury [Powell, JS et al. (1989) Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. *Science* 245:186-8; Powell, JS et al. (1991) The proliferative response to vascular injury is suppressed by converting enzyme inhibition. *J Cardiovasc Pharmacol* 16 (suppl 4):S42-9; Capron, L et al. (1991) Effect of ramipril, an inhibitor of angiotensin converting enzyme, on the response of rat thoracic aorta to injury with a balloon catheter. *J Cardiovasc Pharmacol* 18:207-11; Osterriedes, W et al. (1991) Role of angiotensin II injury-induced neointima formation in rats. *Hypertension* 18:Suppl II60-64; Daemen, MJAP et al. (1991) Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. *Circ Res* 68:450-6]. As a result of these observations, studies were conducted to determine the

mechanism by which endogenous AII may induce intimal hyperplasia. AII was shown to act as a mitogen for smooth muscle cells, fibroblasts and endothelial cells [Schelling, P et al. (1979) Effects of angiotensin II and angiotensin II antagonist saralysin on cell growth and renin in 3T3 and SV3T3 cells. J Cell Physiol 98:503-13; Campbell-Boswell, M and AL Robertson. (1981) Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 35:265-76; Emmett, N et al. (1986) Effect of saralasin (angiotensin II antagonist) on 3T3 cell growth and proliferation. J Cell Biol 103:171 (Abst); Paquet, JL et al. (1990) Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 8:565-72; Dzau et al, *supra*]. AII also increased the protein content and size of vascular smooth muscle cells [Berk et al. (1989), *supra*; Geisterfer, AAT et al. (1988) Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62:749-56]. Studies showed that AII increases the release of growth factors of various types, including PDGF, heparin-binding EGF and transforming growth factor- $\beta$  (TGF $\beta$ ), and growth-related proto-oncogenes from smooth muscle cells, endothelial cells and cardiac fibroblasts [Kawahara et al. (1988), *supra*; Naftilan, AJ (1992) The role of angiotensin II in vascular smooth muscle cell growth. J Cardiovas Pharmacol 20:S37-40; Naftilan et al. (1989), *supra*; Taubman et al. (1989), *supra*; Nakahara et al. (1992), *supra*; Temizer et al (1992), *supra*; Gibbons, GH et al. (1992) Vascular smooth muscle cell hypertrophy vs hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 90:456-61; Bell, L et al. (1992) Autocrine angiotensin system regulation of bovine aortic endothelial cell migration and plasminogen activator involves modulation of proto-oncogene pp60c-src expression. J Clin Invest 89:315-20; Stouffer and Owens (1992), *supra*]. The hypertrophy of vascular smooth muscle cells by AII was mediated through PDGF [Berk, BC and GN Rao. (1993) Angiotensin II-induced vascular smooth muscle cell hypertrophy: PDGF A-chain mediates the increase in size. J Cell Physiol 154:368-80].

Therefore, it is conceivable that AII acts to accelerate wound repair through increasing the levels of these growth factors in the wound tissue. Additionally, AII was shown to stimulate collagen synthesis thereby suggesting a role for this factor in extracellular matrix formation [Wolf, G et al. (1991) Intracellular signalling of

transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells. Cell Reg 2:219-27; Wolf et al. (1992), *supra*; Zhou, G et al. (1992) Angiotensin II mediated stimulation of collagen synthesis in cultured cardiac fibroblasts. FASEB J 6:A1914]. Wound repair also involves chemotaxis of the necessary cell types into the wound bed. AII was also shown to induce the migration of endothelial cells and smooth muscle cells in vitro [Bell and Madri (1990), *supra*].

Recent studies also indicate that expression of AII receptors is altered during the process of wound repair [Viswanathan, M, and JM Saavedra (1992) Expression of Angiotensin II AT<sub>2</sub> Receptors in the Rat Skin During Experimental Wound Healing. Peptides 13:783-6; Kimura, B et al. (1992) Changes in skin angiotensin II receptors in rats during wound healing. BBRC 187:1083-1090]. These changes, along with evidence of an increase in the local production of AII at the site of repair, suggests that AII may play a key role in the process of wound repair.

It has been observed that AII and AIII have quite different biological activities in several respects. For example, AII showed a biphasic effect on evoked neuronal norepinephrine release (an earlier decrease followed by a later increase), while increasing spontaneous norepinephrine release only after 12 minutes; AIII showed a biphasic effect on both evoked and spontaneous neuronal norepinephrine release [Vatta, MS et al. (1992) Monophasic and biphasic effects of angiotensin II and III on norepinephrine uptake and release in rat adrenal medulla. Can. J. Physiol. Pharmacol. 70:821]. Moreover, AII and AIII show differential influences on the baroreceptor-heart-reflex: AII enhances the sensitivity of the reflex, whereas AIII impairs it [Brattstrom, A. et al. (1992) Neuropeptides within the nucleus tractus solitarius modulate the central cardiovascular control process. Progress in Brain Research 91:75]. Surprisingly, notwithstanding these significant differences in biological activity between angiotensin II and angiotensin III, AIII and particular analogs thereof are useful in accelerating wound healing.

Many studies have focused on AII(1-7) to evaluate its activity. Many of the effects of AII(1-7) are attributed to acting through the AT<sub>2</sub> receptor. However, this is not consistent and depends upon the tissue examined.

AII(1-7) does not have many of the effects of AII. AII(1-7) lacks pressor

activity or has very mild (effective at 10000-100000 times the dose of AII) effects on blood pressure depending upon the model tested and route of administration. In fact, AII(1-7) has a depressor effect on blood pressure that may be mediated through prostanoid synthesis. In addition, in contrast to the effects of AII, AII(1-7) does not cause catecholamine release and aldosterone release and is not dipsogenic [Webb et al. 1992. Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cells. Peptides 13:499-508; Cheng et al. 1994. Comparison of pressor responses to angiotensin I, II and III in pulmonary vascular bed of cats. Am. J Physiol 266:H2247-H2255; Moriguchi, A et al. 1994. Differential regulation of central vasopressin in transgenic rats harboring the mouse Ren-2 gene. Am J Physiol 267:R786-R791; Schiavone et al. 1990. Angiotensin-[1-7]: Evidence for novel actions in the brain. J Cardiovascular Pharmacol 16(Suppl 4):S19-S24; Ferrario et al. 1991. Angiotensin-(1-7): A new hormone of the angiotensin system. Hypertension 19[suppl III]:III-126-III-133].

In one report, AII(1-7) is a weak pressor that requires about 10000x more AII(1-7) than AII to get a comparable response [Benter et al. 1993. Cardiovascular actions of angiotensin(1-7). Peptides 14:679-684]. In this system, AII(1-7) had a long depressor effect that was dose dependent. AII(3-7) had less of a pressor effect than AII(1-7), but had no depressor effect. It is also noted that AII(1-7), AII(2-7) and AII(3-7) may affect the dopamine system and memory (suggesting a psychoactive effect).

In several systems, the actions of AII(1-7) are quite distinct from AII. AII stimulates choline production in rat mesangial cells through the AT1 receptor; AII(1-7) and AII(1-6) has very weak effects on this parameter [Pfeilschifter et al. 1992. Angiotensin II stimulation of phospholipase D in rat renal mesangial cells is mediated by the AT1 receptor subtype. Eur J Pharmacol 225:57-62].

In porcine aortic endothelial cells, AI and AII(1-7) stimulated the release of prostaglandin E2 and I2, but AII did not have this effect [Jaiswal et al. 1992. Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension 19 (Suppl II):11-49-II-55]. AII is able to stimulate the release of prostanoids in other cells types and in intact blood vessels but not human or porcine endothelial cells. This effect on endothelial cells was through a

receptor distinct from AT1 and AT2.

In rat glomerulus preparations, AII inhibited the formation of cAMP in response to histamine, serotonin and parathyroid hormone through the AT1 receptor [Edwards, RM and EJ Stack. 1993. Angiotensin II inhibits glomerular adenylate cyclase via the angiotensin II receptor subtype 1 (AT1). *J Pharmacol Exper Ther* 266:506-510]. AII(1-7) did not have this effect.

In porcine vascular smooth muscle cells and human astrocytes, AII and AI(1-7) increases prostaglandin release; only angiotensin II increases the release of intracellular  $Ca^{2+}$  [Jaiswal et al. 1993. Differential regulation by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. *J Pharmacol and Exp Therapeutic* 265:664-673; Jaiswal et al. 1991. Subtype 2 angiotensin receptors mediate prostaglandin synthesis in human astrocytes. *Hypertension* 17:1115-1120].

AII(1-7) dilates porcine coronary artery rings, perhaps through nitric oxide [Porsti et al. 1994. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. *Br. J Pharmacol* 111:652-654]. This was not observed with AII, AIII or AII(3-8). This effect was not attenuated by antagonists of AT1 or AT2 receptors.

AII causes depolarization of rat isolated nodose ganglion; AII(1-7) does not [Widdop et al. 1992. Electrophysiological responses of angiotensin peptides on the rat isolated nodose ganglion. *Clin and Exper Hyper-Theory and Practice* A14:597-613]. Indeed, AII(1-7) may have novel actions on brain function [Schiavone et al. 1990. Angiotensin-[1-7]: Evidence for novel actions in the brain. *J Cardiovascular Pharmacol* 16(Suppl 4):S19-S24].

There are activities that AII(1-7) shares with AII, such as release of vasopressin and modulation of phospholipase A2 activity in proximal tubule cells [Andreatta-Van Leyen, S et al. 1993. Modulation of phospholipase A2 activity and sodium transport by angiotensin-(1-7). *Kidney International* 44:932-6; Moriguchi, A et al. 1994. Differential regulation of central vasopressin in transgenic rats harboring the mouse Ren-2 gene. *Am J Physiol* 267:R786-R791; Ferrario et al. 1991. Angiotensin-(1-7): A new hormone of the angiotensin system. *Hypertension* 19[suppl III]:III-126-III-133]. These activities, however, are likely not involved in wound repair.

The effects of other fragments of AII have been studied in very few instances. Most neurons in the paraventricular nucleus are excited by Ang(1-7), AII and AIII, but AII(1-7) is weaker in this effect; in many neurons, AII(2-7) was inactive [Ambuhl et al. 1992. Effects of angiotensin analogues and angiotensin receptor antagonists on paraventricular neurones. *Regulatory Peptides* 38:111-120]. AII injected in the lateral cerebral ventricle increased the motility, stereotypy and learning of conditioned avoidance responses; AII(1-6) and AII(2-6) were not active in these psychotropic activities [Holy, Z et al. 1993. Psychotropic effects of angiotensin II N-terminal fragments: Asp-Arg-Val-Tyr-Ile-His and Arg-Val-Tyr-Ile-His in rats. *Polish J Pharmacol* 45:31-41].

AII(4-8), AII(5-8) and AII(1-4) showed only a slight effect on water intake when injected into the anterior diencephalon in the rat, and AII(1-7) was completely inactive [Fitzsimmons, JT. 1971. The effect on drinking of peptide precursors and of shorter chain peptide fragments of angiotensin II injected into the rat's diencephalon. *J Physiol* 214:295-303]. Intracerebroventricular infusion of AII fragments [AII(4-8) and AII(5-8)] in the rat produced a minimal effect on blood pressure even when given at concentrations 1000x higher than that of AII that increased blood pressure [Wright et al. 1989. Structure-function analyses of brain angiotensin control of pressor action in rats. *Am J Physiol* 257:R1551-R1557]. In both of these studies, the fragments were injected directly into the brain; this is highly artificial and does not allow for systemic metabolism.

According to the method of the invention, an active fragment or analog thereof in accordance with the present invention is applied to wound tissue in amounts sufficient to increase the healing rate of tissue. These compounds can significantly accelerate the rate of healing at nanomolar levels *in vivo*. For any given active agent, the optimum concentration for a given formulation may readily be determined empirically. In general, an amount of active agent suitable for use in accordance with the present invention ranges from about 0.0001  $\mu$ g to about 10 mg per kilogram body weight.

The compounds of the invention may be applied in a variety of solutions. Suitable solutions for use in accordance with the present invention are sterile, dissolve sufficient amounts of the peptide, and are not harmful to wound tissue. In this



regard, the compounds of the present invention are very stable but are hydrolyzed by strong acids and bases. The compounds of the present invention are soluble in organic solvents and in aqueous solutions at pH 5-8.

5 Any type of application means may be employed which permits the influx of the active agents into the tissue over a period of time. For example, an aqueous solution could be applied to the wound tissue through a gauze bandage or strip, or such a solution could be formulated so that a timed perfusion may be obtained (using, e.g., liposomes, ointments, micelles, etc). Methods for the production of these formulations with the compounds of the present invention are apparent to those of  
10 ordinary skill in the art. The particular concentration of active agent employed is not critical, as the tissue-repairing effect is present even when the compounds are present in nanomolar quantities.

Preferably, a matrical or micellar solution is employed with the active agent present in a concentration of at least 30 micrograms per milliliter. A particular  
15 matrical solution which has been used to advantage in the described examples is a semi-solid polyethylene glycol polymer sold under the trademark Hydron by Hydro Med Sciences, New Brunswick, New Jersey. Another preferred solution is a micellar solution sold under the trade name Pluronic F108 by BASF, Ludwigshafen, Germany. Under room temperature conditions, this solution is a liquid, but when applied to  
20 warm tissue the solution forms a gel which permits the infusion of active agent into the wound tissue for a period of several days. Other preferred formulations include carboxymethyl cellulose preparations (as used in the example herein), crystalloid preparations (e.g., saline, Ringer's lactate solution, phosphate-buffered saline, etc.), viscoelastics, polyethylene glycols, polypropylene glycols and wound dressings (e.g.,  
25 bandages, etc.).

The healing effects of the compounds of the present invention may be provided in a variety of instances. The solution may be applied topically to surface wound tissue in the treatment of ulcers, lesions, injuries, diabetic ulcers, burns, trauma, stasis ulcers, periodontal conditions, lacerations and other conditions. In  
30 addition, intraperitoneal wound tissue such as that resulting from invasive surgery may be treated with a composition in accordance with the present invention to accelerate healing. For example, following the surgical removal of a colon section or other

tissue, the surgical plane may be coated with a solution of active agent prior to closing the surgical site in order to accelerate internal capillary perfusion and healing. In addition, the rate of localized healing may be increased by the subdermal administration of active agent by injection or otherwise.

5           The invention may be better understood with reference to the accompanying example, which is intended for purposes of illustration only and should not be construed as in any sense limiting the scope of the invention as defined in the claims appended hereto.

Example 1

10           Male Sprague Dawley rats, 12 weeks old, were obtained from Simonsen Laboratories, Gilroy, CA. On the day of surgery, the rats received intramuscular ketamine/rompum anesthesia prior to preparation for surgery. The rats were shaved and scrubbed with betadine. Four 2 x 2 cm full thickness dermal wounds were created on the dorsal surface of the rat. Following excision of the skin, the size of the wound was outlined on a glass slide and the medicament was administered in 100  $\mu$ l Hydron solution comprising 10% Hydron, 1% polyethylene glycol (MW 400) and 60% ethanol. The test materials were administered in a randomized fashion; angiotensin III was evaluated at 3 and 10  $\mu$ g/wound. Controls were treated with vehicle only.

15           After administration of the materials, the rats were bandaged and allowed to recover from anesthesia. At days 2, 5, 6, 8 and 10, the area of the skin wounds were measured under methoxyflurane anesthesia (commercially available as Metofane from Pittman-Moore, Mundelein, IL). The area of the wound was determined by: (1) tracing the wound shape onto graph paper (1 x 1 mm squares); (2) cutting out the shape; (3) weighing the paper and comparing the weight with a 2 x 2 cm paper cutout; and (4) counting the number of squares.

20           As illustrated in Fig. 1, wound closure was substantially accelerated relative to the control animals when the test animals were treated with angiotensin III, at both the 3  $\mu$ g and the 10  $\mu$ g dosages. Fig. 1 illustrates the percent increase in wound closure relative to a vehicle-treated control.

25           Example 2

30           Female Sprague Dawley rats, 12 weeks old, were obtained from Simonsen Laboratories, Gilroy, CA and prepared for surgery as in Example 1. Two 1.5 x 1.5 cm

full thickness dermal wounds were created on the dorsal surface of the rat. Following excision of the skin, the size of the wound was outlined on a glass slide and the medicament was administered in 100  $\mu$ l Hydron solution comprising 10% Hydron, 1% polyethylene glycol (MW 400) and 60% ethanol. The test materials were administered in a randomized fashion; all materials were tested at 10  $\mu$ g/wound. Controls were treated with vehicle only. After administration of the materials, the rats were bandaged and allowed to recover from anesthesia. At days 2-3, 5, 7-8 and 9-10, the area of the skin wounds were measured (for analogs 1A and 2-8) under methoxyflurane anesthesia (commercially available as Metofane from Pittman-Moore, Mundelein, IL). The area of the wound was determined by: (1) tracing the wound shape onto graph paper (1 x 1 mm squares); (2) cutting out the shape; (3) weighing the paper and comparing the weight with a 1.5 x 1.5 cm paper cutout; and (4) counting the number of squares. In addition, on days 2-3, 5 and 8, the area of granulation tissue was similarly determined (for analogs 1A, 1B and 2-7). The analogs employed were the following:

|           |                                   |
|-----------|-----------------------------------|
| Analog 1A | Ile <sup>7</sup> -angiotensin III |
| Analog 1B | Val <sup>4</sup> -angiotensin III |
| Analog 2  | Lys <sup>1</sup> -angiotensin III |
| Analog 3  | Ala <sup>2</sup> -angiotensin III |
| Analog 4  | Thr <sup>1</sup> -angiotensin III |
| Analog 5  | Leu <sup>4</sup> -angiotensin III |
| Analog 6  | Arg <sup>1</sup> -angiotensin III |
| Analog 7  | Ala <sup>6</sup> -angiotensin III |
| Analog 8  | Tyr <sup>7</sup> -angiotensin III |

As illustrated in Figures 2-5 attached hereto, wound closure was substantially accelerated relative to the control wounds when the test wounds were treated with Analogs 1-8 in accordance with general formula I. Figures 2 and 3 illustrate the percent of control response in wound closure relative to a vehicle-treated control; in every case, administration of one of the analogs accelerated the closure of the wound after surgery. Figures 4 and 5 illustrate the percent of control response in formation of granulation tissue; again, in every case administration of one of the analogs accelerated the formation of granulation tissue compared to administration of vehicle

alone. Therefore, these analogs clearly are effective in promoting wound healing.

### Example 3

Female Sprague Dawley rats, 175-200 g, were obtained from Simonsen Laboratories, Gilroy, CA. On the day of surgery, the rats received intramuscular ketamine/rompum anesthesia prior to preparation for surgery. The rats were shaved and scrubbed with betadine. Two 1.5 x 1.5 cm full thickness dermal wounds were created on the dorsal surface of the rat. Following excision of the skin, the size of the wound was outlined on a glass slide and the medicament was administered in 100  $\mu$ l 10% low viscosity carboxymethyl cellulose (Sigma). The test materials were administered in a randomized fashion; all materials were tested at 100  $\mu$ g/wound. Controls were treated with vehicle only. After administration of the materials, the rats were bandaged and allowed to recover from anesthesia. On days 1-4 after surgery, the rats were treated with an additional 100  $\mu$ g of peptide formulation. At days 2, 4, 7 and 9, the area of the skin wounds were measured under methoxyflurane anesthesia (commercially available as Metofane from Pittman-Moore, Mundelein, IL). The area of the wound was determined by: (1) tracing the wound shape onto graph paper (1 x 1 mm squares); (2) cutting out the shape; (3) weighing the paper and comparing the weight with a 1.5 x 1.5 cm paper cutout; and (4) counting the number of squares. In addition, on days 2, 4 and 7, the area of granulation tissue was similarly determined.

As illustrated in Figs. 6-11, wound closure was substantially accelerated relative to the control animals when the test animals were treated with all fragments except AII(6-8) and AII(4-8). Figs. 6 and 7 illustrate the percent of control response in wound closure relative to a vehicle-treated control using fragments of AII as herein defined. Figs. 8-11 illustrate the percent of control response in formation of granulation tissue; Figs. 8 and 9 reflect data from control wounds to which Figs. 10 and 11, respectively, should be compared.

From the foregoing description, one skilled in the art can readily ascertain the essential characteristics of the invention and, without departing from the spirit and scope thereof, can adapt the invention to various usages and conditions. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient, and although specific terms have been employed herein, they are

intended in a descriptive sense and not for purposes of limitation.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Rodgers, Kathleen E.  
diZerega, Gere S.
- (ii) TITLE OF INVENTION: USE OF ANGIOTENSIN II FRAGMENTS AND  
ANALOGS THEREOF IN TISSUE REPAIR
- (iii) NUMBER OF SEQUENCES: 14
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: c/o Robbins, Berliner & Carson
  - (B) STREET: 201 North Figueroa Street #500
  - (C) CITY: Los Angeles
  - (D) STATE: CA
  - (E) COUNTRY: USA
  - (F) ZIP: 90012
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Spitals, John P.
  - (B) REGISTRATION NUMBER: 29,215
  - (C) REFERENCE/DOCKET NUMBER: 1920-360
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (213) 977-1001
  - (B) TELEFAX: (213) 977-1003

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Asp Arg Val Tyr Ile His Pro Phe  
1 5

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Arg Val Tyr Ile His Pro Phe  
1 5

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Val Tyr Ile His Pro Phe  
1 5

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Asp Arg Val Tyr Ile His Pro  
1 5

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Arg Val Tyr Ile His Pro  
1 5

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Val Tyr Ile His Pro  
1 5

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear



(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ile His Pro Phe  
1

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Asp Arg Val Tyr Ile His  
1 5

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Asp Arg Val Tyr Ile  
1 5

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Asp Arg Val Tyr  
1

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Asp Arg Val  
1

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

His Pro Phe  
1

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Tyr Ile His Pro Phe  
1 5

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear


(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Xaa Xaa Tyr Xaa His Pro Phe  
1 5

## WHAT IS CLAIMED IS:

1. A method of accelerating wound healing, comprising applying to a wound an amount effective to accelerate wound healing of at least one active agent characterized as comprising a sequence consisting of at least three contiguous amino acids corresponding to a subsequence of groups  $R^1$ - $R^8$  in general formula I



in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group and a peptide bond between  $R^A$  and  $R^B$  is labile to aminopeptidase A cleavage;

$R^3$  is selected from the group consisting of Val, Ala, Leu, Ile, Gly, Pro, Aib, Acpc and Tyr;

$R^4$  is selected from the group consisting of Tyr, Thr, Ser and azaTyr;

$R^5$  is selected from the group consisting of Ile, Ala, Leu, Val and Gly;

$R^6$  is His or Arg;

$R^7$  is Pro or Ala; and

$R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences wherein  $R^4$  is a terminal Tyr group.

2. A method according to claim 1, wherein  $R^A$  is selected from the group consisting of Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc.

3. A method according to claim 1, wherein  $R^B$  is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys.


4. A method according to claim 1, wherein the active agent is administered in a matrical or micellar solution.

5. A method according to claim 1, wherein the active agent is administered at a rate of at least 0.1 ng per kg body weight in a suitable carrier or diluent.


30 6. A method according to claim 5, wherein the carrier or diluent is selected from the group consisting of carboxymethyl cellulose preparations, crystalloid preparations, viscoelastics, polyethylene glycols and polypropylene glycols.

7. A method according to claim 1, wherein the active agent is administered in conjunction with a wound dressing.

8. A composition for accelerating wound healing, comprising a suitable carrier or diluent and an amount effective to accelerate wound healing of at least one active agent characterized as comprising a sequence consisting of at least three contiguous amino acids corresponding to a subsequence of groups  $R^1$ - $R^8$  in general formula I



in which  $R^1$  and  $R^2$  together form a group of formula



10 wherein X is H or a one to three peptide group and a peptide bond between  $R^A$  and  $R^B$  is labile to aminopeptidase A cleavage;

$R^3$  is selected from the group consisting of Val, Ala, Leu, Ile, Gly, Pro, Aib, Acpc and Tyr;

15  $R^4$  is selected from the group consisting of Tyr, Thr, Ser and azaTyr;

$R^5$  is selected from the group consisting of Ile, Ala, Leu, Val and Gly;

$R^6$  is His or Arg;

$R^7$  is Pro or Ala; and

20  $R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences wherein  $R^4$  is a terminal Tyr group.

9. A composition according to claim 8, wherein R<sup>a</sup> is selected from the group consisting of Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc.

10. A composition according to claim 8, wherein R<sup>b</sup> is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys.

11. A composition according to claim 8, wherein the active agent is administered in a matrical or micellar solution.

12. A composition according to claim 8, wherein the active agent is administered at a rate of at least 0.1 ng per kg body weight in a suitable carrier or diluent.

13. A composition according to claim 12, wherein the carrier or diluent is selected from the group consisting of carboxymethyl cellulose preparations, crystalloid preparations, viscoelastics, polyethylene glycols and polypropylene glycols.

14. A composition according to claim 8, wherein the active agent is administered in conjunction with a wound dressing.

# Full Thickness Wounds All




FIG. 1

# AIII ANALOGUES WOUND SIZE




FIG. 2



# AIII ANALOGUES

## WOUND SIZE




FIG. 3

# AIII ANALOGUES

## GRANULATION TISSUE

WO 96/14858

PCT/US95/14764




FIG. 4

# AIII ANALOGUES

## GRANULATION TISSUE




FIG. 5

# CONTROL SIZE




FIG. 6

# CONTROL SIZE

## % Control Response




FIG. 7

# GRANULATION CONTROL WOUNDS




FIG. 8

# GRANULATION TISSUE CONTROL WOUNDS




FIG. 9

# GRANULATION

## TREATED WOUNDS




FIG. 10



# GRANULATION TISSUE TREATED WOUNDS




FIG. 11

# GRANULATION CONTROL WOUNDS




FIG. 12

# GRANULATION TREATED WOUNDS




FIG. 13

# CONTROL SIZE




FIG. 14

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/JS 95/14764

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K38/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                      | Relevant to claim No. |
|------------|---|-----------------------|
| X          | US,A,5 015 629 (DIZEREGA G.S.) 14 May 1991<br>cited in the application<br>see the whole document<br>--- | 1,8                   |
| P,X        | WO,A,95 08337 (THE UNIVERSITY OF SOUTHERN CALIFORNIA) 30 March 1995<br>see the whole document<br>---    | 1-14                  |
| P,X        | WO,A,95 08565 (THE UNIVERSITY OF SOUTHERN CALIFORNIA) 30 March 1995<br>see the whole document<br>-----  | 1-14                  |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

- \* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \* "A" document member of the same patent family

Date of the actual completion of the international search

27 March 1996

Date of mailing of the international search report

11.04.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Moreau, J

# INTERNATIONAL SEARCH REPORT

national application No.

PCT/US95/14764

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 1-7 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 95/14764

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| US-A-5015629                              | 14-05-91            | NONE                       |                     |
| WO-A-9508337                              | 30-03-95            | AU-B- 7730294              | 10-04-95            |
| WO-A-9508565                              | 30-03-95            | AU-B- 7836494              | 10-04-95            |